At the University of New Mexico School of Medicine in Albuquerque, New Mexico (SKS) the Department of Urology just completed a study that showed that dutasteride, the generic name for a dual 5alpha-reductase inhibitor made by GlaxoSmithKline and marketed under the name Avodart™ in the US and Avolve™ in Europe, when administered to men with [...]
FDA just approved th first gonsdotropin-releasing hormone (GnRH) drug for the treatment of Advanced Prostate Cancer. This newly approved gonadotropin-releasing hormone (GnRH) receptor antagonist demonstrates rapid, long-term suppression of testosterone. Ferring Pharmaceuticals, USA (FP) received approval from the U.S. Food and Drug Administration (FDA) for degarelix, (generic name) which is a new injectable gonadotropin-releasing hormone [...]
Many members of Congress see the potential of an increased investment in the NIH as part of the solution to our ailing economy. We prostate cancer survivors can glean additional benefits from an increase to NIH funding, in our fight against this terrible disease. The belief that making an increased economic investment in research through [...]
I had my second chemo treatment last week (Thursday) and it went so much faster with the port-a-cath (see the December 1, 2008 post “Injection Site Issues and Technology” for an explanation of a port-a-cath). As most of us who are traveling this trail will know, our veins take a regular beating from all of [...]
What is left for us once we become resistant to docetaxel (DOC) plus prednisone, which is the last FDA approved, standard of care treatment available for advanced hormone refractory prostate cancer? There has been some studies that indicate after a “vacation period” similar to what many of us do with a first line hormone blockade, [...]